From Wikipedia - Reading time: 5 min
| Company type | Sociedad Anónima |
|---|---|
| BMAD: ZEL | |
| ISIN | ES0184940817 |
| Industry | Pharmaceutical |
| Founded | Vigo, Galicia, Spain (August 3, 1939) |
| Defunct | 2015 |
| Headquarters | Madrid , Spain |
Area served | Worldwide |
Key people | José Fernández Sousa-Faro (Chairman) |
| Products | Pharmaceuticals |
| Revenue | |
| Total assets | |
| Total equity | |
| Subsidiaries | PharmaMar, Genómica, Sylentis, Zelnova, Xylazel |
| Website | www |
| Footnotes / references [finan 1][history 1] | |
Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product.[history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns.[history 3]
In 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal.[1]
The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure.
In 2018 PharmaMar sells Xylazel to the Dutch company AkzoNobel.[2][3]
In 2019 PharmaMar sells Zelnova, the group's last subsidiary in Galicia, to the Galician investment company Allentia Invest for 33 million euros.[4]
Direct subsidiaries as of 2009 were:[finan 2] Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A.
Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were:[finan 2] Pharma Mar US; Pharma Mar AG; PharmaMar S.A.R.L.; Pharma Mar GmbH; Pharma Mar Ltd.
A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A.[finan 2]